MEI Pharma Analyst Ratings
MEI Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 22.62% | Stifel | $10 → $9 | Maintains | Hold |
| 05/23/2023 | 989.92% | Brookline Capital | → $80 | Maintains | Buy |
| 05/12/2023 | 36.24% | Stifel | $0.5 → $10 | Maintains | Hold |
| 02/13/2023 | -72.75% | HC Wainwright & Co. | $5 → $2 | Maintains | Buy |
| 02/08/2023 | -98.64% | Jefferies | $0.4 → $0.1 | Downgrades | Hold → Underperform |
| 12/06/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | -45.5% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | -59.13% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | -31.88% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | -72.75% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | -72.75% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | -86.38% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | -45.5% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 117.98% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 36.24% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/27/2023 | 22.62% | Stifel | 10 美元 → 9 美元 | 維護 | 保持 |
| 05/23/2023 | 989.92% | 布魯克林資本 | → 80 美元 | 維護 | 購買 |
| 05/12/2023 | 36.24% | Stifel | 0.5 美元 → 10 美元 | 維護 | 保持 |
| 02/13/2023 | -72.75% | HC Wainwright & Co. | 5 美元 → 2 美元 | 維護 | 購買 |
| 02/08/2023 | -98.64% | 傑富瑞 | 0.4 美元 → 0.1 美元 | 降級 | 持有 → 表現不佳 |
| 12/06/2022 | — | BTIG | 降級 | 買入 → 中性 | |
| 12/06/2022 | — | 信實證券 | 降級 | 買入 → 持有 | |
| 03/25/2022 | -45.5% | BTIG | 11 美元 → 4 美元 | 維護 | 購買 |
| 03/25/2022 | -59.13% | 信實證券 | 8 美元 → 3 美元 | 維護 | 購買 |
| 03/25/2022 | -31.88% | HC Wainwright & Co. | 10 美元 → 5 美元 | 維護 | 購買 |
| 03/25/2022 | -72.75% | 富國銀行 | 13 美元 → 2 美元 | 降級 | 超重 → 重量相等 |
| 03/25/2022 | -72.75% | Stifel | 6 美元 → 2 美元 | 降級 | 買入 → 持有 |
| 03/25/2022 | -86.38% | 傑富瑞 | 4 美元 → 1 美元 | 降級 | 買入 → 持有 |
| 2022 年 3 月 2 日 | -45.5% | 傑富瑞 | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 5 月 29 日 | 117.98% | SunTrust 羅賓遜·漢弗萊 | → 16 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/13/2019 | — | BTIG | 啓動覆蓋範圍開啓 | → 購買 | |
| 2018 年 12 月 20 日 | 36.24% | HC Wainwright & Co. | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的目標價格是多少？
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by Stifel on September 27, 2023. The analyst firm set a price target for $9.00 expecting MEIP to rise to within 12 months (a possible 22.62% upside). 7 analyst firms have reported ratings in the last year.
Stifel於2023年9月27日公佈了MEI Pharma（納斯達克股票代碼：MEIP）的最新目標股價。該分析公司將目標股價定爲9.00美元，預計MEIP將在12個月內上漲至22.62％（可能上漲22.62％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的最新分析師評級是多少？
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by Stifel, and MEI Pharma maintained their hold rating.
Stifel提供了MEI Pharma（納斯達克股票代碼：MEIP）的最新分析師評級，MEI Pharma維持其持倉評級。
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與MEI Pharma的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。MEI Pharma的最後一次評級是在2023年9月27日提交的，因此你應該預計下一個評級將在2024年9月27日左右公佈。
Is the Analyst Rating MEI Pharma (MEIP) correct?
分析師對MEI Pharma（MEIP）的評級是否正確？
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $10.00 to $9.00. The current price MEI Pharma (MEIP) is trading at is $7.34, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的MEI Pharma（MEIP）評級保持不變，目標股價爲10.00美元至9.00美元。MEI Pharma（MEIP）目前的交易價格爲7.34美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。